Retevmo is the first FDA-approved therapy that targets RET alterations specifically in patients with RET-positive metastatic non-small cell lung cancer (NSCLC) and advanced thyroid cancers.
It is not chemotherapy, immunotherapy, or radiation therapy, and can be taken at home.
Retevmo is a prescription medicine that is used to treat certain cancers caused by abnormal RET genes in adults with non-small cell lung cancer (NSCLC) that has spread, adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy), and adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working.
Your healthcare provider will perform a test to make sure that Retevmo is right for you. It is not known if Retevmo is safe and effective in children younger than 12 years of age.
Retevmo was approved based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long the response lasted. Studies are ongoing to confirm the benefit of Retevmo for this use.
A biomarker test is the only way to discover if you have a RET alteration, which will determine if Retevmo may be able to help you. To learn more about this targeted therapy and biomarker testing, talk to your doctor.
Retevmo may affect both healthy cells and tumor cells, which can result in side effects, some of which can be serious.
Learn More About Retevmo
Savings & Support
For information about Retevmo Ongoing Support and financial assistance for eligible patients, including co-pay assistance, please call the Lilly Oncology Support Center at 1-866-472-8663 , Monday-Friday from 8 AM to 10 PM ET.Download Savings Card
Governmental beneficiaries excluded, terms and conditions apply.